Hereditary Angioedema Treatment Market Regional Analysis

Global Hereditary Angioedema Treatment Market size was valued at USD 2.7 billion in 2023 and is poised to grow from USD 2.77 billion in 2024 to USD 3.37 billion by 2032, growing at a CAGR of 2.5% during the forecast period (2025-2032).

The global hereditary angioedema treatment market is fragmented, with a prominent market player acquiring a sizable portion. Some of the market's leading companies such as Takeda Pharmaceutical Company Limited, CSL Limited, BIOCRYST PHARMACEUTICALS, INC., Pharming Group N.V., Ionis Pharmaceuticals, Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., AstraZeneca, Medtronic are forming multiple strategic alliances in order to increase their market share and get a competitive edge. 'CSL Behring (Australia) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Pharming Group N.V. (Netherlands) ', 'BioCryst Pharmaceuticals, Inc. (USA) ', 'Ionis Pharmaceuticals, Inc. (USA) ', 'Sanofi S.A. (France) ', 'Adverum Biotechnologies, Inc. (USA) ', 'KalVista Pharmaceuticals, Inc. (USA) ', 'Attune Pharmaceuticals, Inc. (USA) ', 'Arrowhead Pharmaceuticals, Inc. (USA) ', 'Amgen Inc. (USA) ', 'BioMarin Pharmaceutical Inc. (USA) ', 'Catalyst Biosciences, Inc. (USA) ', 'RUCONEST (Pharming Group N.V., Netherlands) ', 'Haegarda (CSL Limited, Australia) ', 'Firazyr (Shire plc, UK) ', 'Dyax Corp. (USA) ', 'Adverum Biotechnologies, Inc. (USA) ', 'Amgen Inc. (USA)'

Researchers and manufacturers around the world are increasing their focus on advanced therapeutics for the treatment of hereditary angioedema disorders and taking the necessary steps to create or advance therapeutics for the treatment of hereditary angioedema disorders. Several manufacturers have recently filed new medication applications in various counties for C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor treatment of Type I, Type II, and Type III HAE. The increased emphasis on sophisticated treatments and innovative drug applications will increase the availability of hereditary angioedema treatment therapies during the forecast period.

Rising awareness of rare conditions and hereditary angioedema in recent years can be credited to the expansion of the global market. The primary factors driving the global market include novel therapeutics, pipeline medications, and new product launches such as Takhzyro, a lanadelumab monoclonal antibody for the treatment of prophylactic HAE. The majority of pipeline medications are oral, due to which the oral method of administration is growing as a trend in the market. This approach is more convenient for patients and has fewer adverse effects. Companies are attempting to get into the rare illnesses industry with novel products in the pipeline. Due to the market expiration, these players may enter the hereditary angioedema treatment market.

North America dominated the global hereditary angioedema therapy market in 2021 and is expected to continue to do so during the forecast period. The high prevalence of hereditary angioedema, substantially better reported disease ratios, high healthcare expenditure, and availability of speciality HAE products are the primary drivers for the growth of the North American hereditary angioedema treatment market.